Tao Shi-Yi, Yu Lin-Tong, Li Jun, Li Yong-Hao, Huang Xuan-Chun, Xue Tian-Tian, Yang De-Shuang, Zheng Chao-Nan
Beijing University of Chinese Medicine Beijing 100029, China Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China.
Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2024 Nov;49(22):6198-6213. doi: 10.19540/j.cnki.cjcmm.20240815.501.
Bayesian network Meta-analysis was conducted to assess the efficacy and safety of different Chinese medicine injections for dilated cardiomyopathy(DCM). CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, Cochrane Library, ProQuest, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov were searched for the randomized controlled trial(RCT) from the inception to January 2024. The quality of the included RCT was evaluated using the Cochrane's risk of bias assessment tool, and the quality of evidence for outcomes was assessed by GRADE. Stata 16.0 and RevMan 5.4 softwares were used for Meta-analysis. A total of 57 RCTs involving 4 812 subjects, 6 Chinese medicine injections and 6 outcome indicators were included. Bayesian network Meta-analysis indicated that:(1) In terms of increasing clinical total effectiveness rate, except Shenqi Fuzheng Injection + conventional western medicine, other 5 Chinese medicine injections combined with conventional western medicine outperformed conventional western medicine alone, and Xinmailong Injection + conventional western medicine had the best effect.(2) In terms of improving left ventricular ejection fraction, all of the 6 Chinese medicine injections combined with conventional western medicine were superior to conventional western medicine alone, and Shengmai Injection + conventional western medicine had the highest likelihood of being the best intervention.(3) On account of reducing left ventricular end-diastolic dimension, Shenfu Injection + conventional western medicine, Shenmai Injection + conventional western medicine, Huangqi Injection + conventional western medicine, and Xinmailong Injection + conventional western medicine outperformed conventional western medicine alone except Shengmai Injection + conventional western medicine, and Huangqi Injection + conventional western medicine had the highest probability of being the best treatment.(4) In terms of decreasing BNP, Huangqi Injection + conventional western medicine, Shenfu Injection + conventional western medicine, and Shenmai Injection + conventional western medicine were better than conventional western medicine alone, and Huangqi Injection + conventional western medicine had the highest likelihood of being the best treatment.(5) Considering the improvement in 6-min walk test, Shenmai Injection + conventional western medicine were superior to conventional western medicine alone.(6) In the case of improving cardiac output, Shenmai Injection + conventional western medicine, Shengmai Injection + conventional western medicine, Xinmailong Injection + conventional western medicine, and Shenqi Fuzheng Injection + conventional western medicine outperformed conventional western medicine alone except Shenfu Injection + conventional western medicine, thereinto, Shenmai Injection + conventional western medicine might be the optimal choice for increasing cardiac output level.(7) For safety, no statistically significant difference in adverse events was recorded between the experimental group and the control group(P=0.24). Bayesian network Meta-analysis showed that the addition of Chinese medicine injections to conventional western medicine exerted a more positive effect for DCM, and had advantages in alleviating clinical symptoms and improving cardiac function. However, due to the overall low quality of the included articles, the low inclusion of certain Chinese medicine injections, and the lack of direct comparison between different Chinese medicine injections, the results need to be further confirmed.
进行贝叶斯网络Meta分析以评估不同中药注射剂治疗扩张型心肌病(DCM)的疗效和安全性。检索中国知网、万方、维普、中国生物医学文献数据库、PubMed、Web of Science、EMbase、Cochrane图书馆、ProQuest、Cochrane对照试验中心注册库、ClinicalTrials.gov,查找从建库至2024年1月的随机对照试验(RCT)。采用Cochrane偏倚风险评估工具评估纳入RCT的质量,并用GRADE评估结局的证据质量。使用Stata 16.0和RevMan 5.4软件进行Meta分析。共纳入57项RCT,涉及4812例受试者、6种中药注射剂和6个结局指标。贝叶斯网络Meta分析结果表明:(1)在提高临床总有效率方面,除参芪扶正注射液联合常规西药外,其他5种中药注射剂联合常规西药均优于单纯常规西药,且心脉隆注射液联合常规西药效果最佳。(2)在提高左心室射血分数方面,6种中药注射剂联合常规西药均优于单纯常规西药,且生脉注射液联合常规西药最有可能是最佳干预措施。(3)在减小左心室舒张末期内径方面,除生脉注射液联合常规西药外,参附注射液联合常规西药、参麦注射液联合常规西药、黄芪注射液联合常规西药及心脉隆注射液联合常规西药均优于单纯常规西药,且黄芪注射液联合常规西药最有可能是最佳治疗方法。(4)在降低脑钠肽方面,黄芪注射液联合常规西药、参附注射液联合常规西药及参麦注射液联合常规西药优于单纯常规西药,且黄芪注射液联合常规西药最有可能是最佳治疗方法。(5)在改善6分钟步行试验方面,参麦注射液联合常规西药优于单纯常规西药。(6)在提高心输出量方面,除参附注射液联合常规西药外,参麦注射液联合常规西药、生脉注射液联合常规西药、心脉隆注射液联合常规西药及参芪扶正注射液联合常规西药均优于单纯常规西药,其中参麦注射液联合常规西药可能是提高心输出量水平的最佳选择。(7)在安全性方面,试验组与对照组不良事件差异无统计学意义(P = 0.24)。贝叶斯网络Meta分析表明,在常规西药基础上加用中药注射剂对DCM有更积极的作用,在缓解临床症状和改善心功能方面具有优势。然而,由于纳入文献总体质量较低,某些中药注射剂纳入较少,且不同中药注射剂之间缺乏直接比较,结果有待进一步证实。